The value of Genentech's Cabilly patent arrangement

from marketwatch: During a call with analysts following release of the company's fourth-quarter earnings late Wednesday, David Ebersman, chief financial officer, said Genentech's revenue from its Cabilly patent arrangement with MedImmune totaled 6 cents a share in 2006 and will increase to 7 cents in 2007.

IPBiz notes that the Supreme Court case established the standing of MedImmune, a licensee paying its royalties, to file a DJ action against patentee Genentech. The question of the underlying validity of the patent was not addressed in the case. The decision makes it easier for licensees to challenge patents without assuming the high risks of injunction and triple damages.